💨 Abstract

The U.S. has launched lenacapavir, a long-acting HIV prevention drug, in Zimbabwe. Over the next three years, 271,000 people will benefit, preventing over 9,000 new infections. The drug, developed by Gilead Sciences, is administered twice a year and aims to improve adherence, particularly among young women and other at-risk groups. The U.S. remains Zimbabwe's largest health-sector donor, contributing over $1.9

Courtesy: Dumani Moyo